A silent pheochromocytoma with regional metastasis and negative germline testing

Biochemical silence does not imply benign pathology. Pheochromocytomas without catecholamine excess can still exhibit malignant potential, thereby highlighting the need for comprehensive testing in all cases. Discordant testing requires integrative assessment. Equivocal biochemical results should not preclude further evaluation or empiric preoperative blockade, especially when imaging features or clinical context raises suspicion. Tumor size is an unreliable risk surrogate. Even small adrenal lesions may harbor aggressive histopathology; risk stratification must incorporate pathology and molecular profiling. Genetic testing is indispensable but not definitive. Comprehensive germline testing informs prognosis and surveillance, yet negative results do not eliminate the possibility of malignant behavior. Long-term surveillance remains essential. High-risk features mandate sustained biochemical and imaging follow-up, regardless of tumor size, biochemical phenotype, or genetic background.

Authors

Institutions

Publication Details

Journal
Endocrinology Diabetes and Metabolism Case Reports
Published
2026-01-01
DOI
https://doi.org/10.1530/edm-25-0124
Primary Topic
Adrenal and Paraganglionic Tumors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A silent pheochromocytoma with regional metastasis and negative germline testing

Shourya Tadisina, Sallam Alrosan, Vasu Bansal, Hana Anan Hamdan et al.
Endocrinology Diabetes and Metabolism Case Reports
Adrenal and Paraganglionic Tumors
article

A silent pheochromocytoma with regional metastasis and negative germline testing

Shourya Tadisina, Sallam Alrosan, Vasu Bansal, Hana Anan Hamdan, Sobrina S Mohammed
article en

Abstract

Biochemical silence does not imply benign pathology. Pheochromocytomas without catecholamine excess can still exhibit malignant potential, thereby highlighting the need for comprehensive testing in all cases. Discordant testing requires integrative assessment. Equivocal biochemical results should not preclude further evaluation or empiric preoperative blockade, especially when imaging features or clinical context raises suspicion. Tumor size is an unreliable risk surrogate. Even small adrenal lesions may harbor aggressive histopathology; risk stratification must incorporate pathology and molecular profiling. Genetic testing is indispensable but not definitive. Comprehensive germline testing informs prognosis and surveillance, yet negative results do not eliminate the possibility of malignant behavior. Long-term surveillance remains essential. High-risk features mandate sustained biochemical and imaging follow-up, regardless of tumor size, biochemical phenotype, or genetic background.

Endocrinology Diabetes and Metabolism Case ReportsVol. 2026(1)
University of Missouri–Kansas City (US)
Openalex Percentile: Top 7%
Adrenal and Paraganglionic Tumors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A silent pheochromocytoma with regional metastasis and negative germline testing — Shourya Tadisina, Sallam Alrosan, et al. · Endocrinology Diabetes and Metabolism Case Reports (2026) | TGRS Research Map | TGRS